Evidence map›Paper›PMID 31171878›Full record

Trial reportNature medicine2019

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V Long, Anna Maria Di Giacomo and 9 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02130466 (A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination With Trametinib and Dabrafenib in Subjects With Advanced Melanoma), which is not on this map. Cited by 178 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
178citing papers in PubMed, 12 pooled it
18.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02130466 phase1 / phase2completednot on this map

A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination With Trametinib and Dabrafenib in Subjects With Advanced Melanoma

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2014 to 2021Enrolled184ConditionsMelanoma, Solid TumorsArmsPembrolizumab, Dabrafenib, Trametinib, Placebo
3 · Its place in the literature

Who cites it

178 citing papers in PubMed, 12 syntheses or guidelines pooled it, 320 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Trial
  14. Trial
  15. Trial
  16. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  17. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With AdvancedJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  18. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  19. Trial
  20. Trial

118 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 17 institutions in 7 countries.

Paolo Antonio Ascierto *Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy. paolo.ascierto@gmail.com.ORCID http://orcid.org/0000-0002-8322-475X
Pier Francesco Ferrucci *European Institute of Oncology IRCCS, Milan, Italy. pier.ferrucci@ieo.it.
Rosalie FisherAuckland City Hospital, Auckland, New Zealand.
Michele Del VecchioFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Victoria AtkinsonGallipoli Medical Research Foundation, Greenslopes Private Hospital, Brisbane, Queensland, Australia.
Henrik SchmidtAarhus University Hospital, Aarhus, Denmark.
Jacob SchachterElla Lemelbaum Institute for Melanoma, Sheba Medical Center at Tel HaShomer, Cancer Center (Oncology Institute), Ramat Gan, Israel.
Paola QueiroloIRCCS San Martino-IST, Genova, Italy.
Georgina V LongMelanoma Institute Australia and the University of Sydney, Mater and Royal North Shore Hospitals, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8894-3545
Anna Maria Di GiacomoCenter for Immuno-Oncology, University Hospital of Siena, Siena, Italy.
Inge Marie SvaneHerlev Hospital, University of Copenhagen, Herlev, Denmark.
Michal LotemSharett Institute of Oncology, Hadassah Hebrew Medical Center, Jerusalem, Israel.
Gil Bar-SelaRambam Health Care Campus, Haifa, Israel.
Felix CoutureCentre Hospitalier Universitaire de Québec Research Center, Laval University, Québec, Québec, Canada.
Bijoyesh MookerjeeNovartis, East Hanover, NJ, USA.
Razi GhoriMerck & Co., Inc., Kenilworth, NJ, USA.
Nageatte IbrahimMerck & Co., Inc., Kenilworth, NJ, USA.
Blanca Homet MorenoMerck & Co., Inc., Kenilworth, NJ, USA.
Antoni Ribas *University of California Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. aribas@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-3669-8458
Merck & Co., Inc., Rahway, NJ, USA (United States) · USAarhus University Hospital · DKAuckland City Hospital · NZCentre hospitalier universitaire de Québec · CAEuropean Institute of Oncology · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGreenslopes Private Hospital · AUHadassah Medical Center · ILIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITNovartis (United States) · USOspedale Policlinico San Martino · ITRambam Health Care Campus · ILRoyal North Shore Hospital · AUSheba Medical Center · ILUniversity of California, Los Angeles · USUniversity of Copenhagen · DKUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses that are induced by the combined inhibition of BRAF and MEK

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsDouble-Blind MethodFemaleHumansImidazolesKaplan-Meier EstimateMaleMAP Kinase Kinase KinasesMelanomaMiddle AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBRAF protein, humandabrafenibImidazolesMAP Kinase Kinase KinasesOximesPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinib

Identifiers

PMID31171878
OpenAlexW2948740360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.